Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Plasmodium apicoplast 50S ribosome is the large subunit of the prokaryotic-like 70S ribosome located within the apicoplast, a non-photosynthetic plastid essential for the survival of malaria-causing parasites (McFadden, 2011; Sidhu et al., 2007). This organelle, derived from an ancient red algal endosymbiont, houses critical metabolic pathways such as isoprenoid biosynthesis, which are vital for the parasite's asexual blood stage (Yeh and DeRisi, 2011). The 50S subunit serves as a primary target for several classes of antibiotics, including macrolides like azithromycin and lincosamides like clindamycin (Dahl and Rosenthal, 2007). These drugs bind to the subunit, typically at the peptide exit tunnel or the peptidyl transferase center, thereby inhibiting protein translation (Sidhu et al., 2007). A hallmark of targeting the apicoplast ribosome is the "delayed death" phenomenon, where the initial generation of parasites remains viable but their progeny fail to survive, necessitating the use of these drugs in combination with faster-acting antimalarials (Dahl and Rosenthal, 2007; Kennedy et al., 2019). Resistance to these agents can emerge through specific mutations in apicoplast-encoded components, such as the 23S ribosomal RNA or the ribosomal protein L4 (Goodman et al., 2013; Sidhu et al., 2007). Understanding the structural and functional nuances of this ribosome is crucial for developing next-generation antimalarials that can overcome existing resistance mechanisms (Gupta et al., 2014).
Inhibition of protein synthesis by binding to the 50S ribosomal subunit, specifically at the peptide exit tunnel or peptidyl transferase center, to block transpeptidation and peptide elongation (Sidhu et al., 2007; Dahl and Rosenthal, 2007).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium apicoplast 50S ribosome (Apicoplast 50S).